Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Background and Aim: Data on the relationship between epidemiological changes in food bolus impaction (FBI) and its relationship to eosinophilic esophagitis (EoE) are limited. The aim of this study ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

Eosinophilic esophagitis is an allergic condition in which eosinophils (white blood cells that play a role in the immune ...

Are you looking for effective medications to treat 'Eosinophilic Esophagitis (EoE)'? This page serves as your comprehensive resource hub, featuring the latest medications, both generic and brand ...

Opens in a new tab or window The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in patients with eosinophilic esophagitis at 24 ...

Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...